EPO treatment was reported to reduce inflammation in the intestine in traumatic brain injury in rats, reducing inflammatory cytokines, TNF-α and interleukin 8 as well as labile zinc accumulation [184], and to reduce injury in liver in rodents in ischemia-reperfusion injury or in high fat diet induced obesity, inhibiting gluconeogenesis and inflammation [185,186]. The gene discussed is EPO; the disease is obesity due to melanocortin 4 receptor deficiency.